Booster Shot Has 95.6% Efficacy Against COVID-19 Leave a comment


  • Pfizer said its booster shot had 95.6% efficacy against COVID-19 caused by the Delta variant.
  • The results were from its first large trial, of more than 10,000 people aged 16 and older.
  • The study hasn’t yet been published or formally scrutinized by other experts.

Fully vaccinated people who received a booster dose of Pfizer’s shot in a large trial were at much lower risk of catching COVID-19, the company said Monday.

This group was at a 95.6% lower risk of catching COVID-19 than fully vaccinated people who received a placebo instead of the booster, the company said.

“These are the first efficacy results from any randomized, controlled COVID-19 vaccine booster trial,” Pfizer said in the press release, adding that it planned to submit the data to health authorities.

The results were from a late stage trial of more than 10,000 people aged 16 or older.

Pfizer Chairman and CEO Albert Bourla said in the statement: “These results provide further evidence of the benefits of boosters as we aim to keep people well-protected against this disease.”

All participants in the trial had already recieved two doses of the Pfizer’s vaccine. Half of them then got the third booster dose, and half got a placebo.

Loading Something is loading.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *